Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide and Diclofenac Interaction Study
NCT02495831Phase 1Completed
- Sponsor
- Zambon
- Start
- May 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of safinamide in Parkinson's disease (PD) (2 arms), sponsored by Zambon. Primary endpoint: Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC at 24 hours. Started May 2015; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02495831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495831.